FDA & Regulatory
FDA Approval Summary: Erdafitinib for FGFR3 -Altered Locally Advanced or Metastatic Urothelial Carcinoma
Maguire et alClinical Cancer Research

On January 19, 2024, the U.S. Food and Drug Administration (FDA) granted traditional approval to erdafitinib for patients with locally advanced or metastatic urothelial carcinoma (la/mUC) with susceptible FGFR3 genetic alterations—identified by an FDA-approved companion diagnostic test—whose disease has progressed on or after at least one line of prior systemic therapy.
Substantial evidence of effectiveness was obtained from Cohort 1 of the open-label trial BLC3001 (THOR, NCT03390504), which randomized 266 patients 1:1 to receive erdafitinib (8 mg once daily with potential uptitration to 9 mg) compared with chemotherapy (docetaxel 75 mg/m² every 3 weeks or vinflunine 320 mg/m² every 3 weeks) until disease progression or unacceptable toxicity. For the primary endpoint of overall survival (OS), the median OS was 12.1 months (95% CI, 10.3–16.4) in the erdafitinib arm compared with 7.8 months (95% CI, 6.5–11.1) in the chemotherapy arm (hazard ratio, 0.64; 95% CI, 0.47–0.88; P = 0.0050). Statistically significant improvements in OS, progression-free survival, and objective response rate were demonstrated for erdafitinib compared with chemotherapy.
Based on BLC3001 Cohort 2 results showing no OS benefit of erdafitinib compared with pembrolizumab (HR, 1.18; 95% CI, 0.92–1.51), the FDA approval includes a limitation of use: erdafitinib is not recommended for the treatment of patients who are eligible for and have not received prior PD-(L)1 inhibitor therapy. The publication summarizes the supporting data and the FDA rationale for not requiring specific types of prior systemic therapy in the indication statement.
Key Takeaways
- Erdafitinib resulted in a median overall survival of 12.1 months versus 7.8 months with chemotherapy (HR, 0.64; 95% CI, 0.47–0.88; P = 0.0050), alongside statistically significant improvements in progression-free survival and objective response rate.
- Cohort 2 showed no overall survival benefit for erdafitinib compared with pembrolizumab (HR, 1.18; 95% CI, 0.92–1.51), leading to an FDA limitation of use stating erdafitinib is not recommended for patients who are eligible for and have not received prior PD-(L)1 inhibitor therapy.
Read the original sourceClinical Cancer Research
